MEDIAN DIAGNOSTICSMM

MEDIAN DIAGNOSTICS

12,500KRWD
−500−3.77%
At close at Jun 13, 10:45 GMT
KRW
No trades
See on Supercharts

233250 fundamentals

Key facts

Market capitalization‪20.51 B‬KRW
Founded1999
CEOJin-Sik Oh
About

Median Diagnostics Inc. engages in the manufacture and supply of in vitro diagnostic products for animal diseases and raw materials for human disease diagnosis. It operates through the following business divisions: Immunodiagnosis, Microbiological diagnosis, Molecular Diagnostics, Clinical chemistry tests, Blood test, and Urine test. The Immunodiagnosis division uses fluorescent labels, enzymes, and other chemical indicators to detect and quantify the analyte. The Microbiological diagnosis division includes identification of bacterial pathogens, virus culture and isolation, and antibiotic susceptibility testing. The Molecular Diagnostics division offers tests for unique nucleic acid sequences. The Clinical Chemistry tests division examines the health of companion animals. The Blood test division deals with the analysis of infections, inflammation, immunodeficiency, anemia, leukemia and other hematological disorders in animals. The Urine test division handles conditions including liver disease, kidney disease and dysfunction, diabetes, infections and other potential diseases. The company was founded on October 18, 1999 and is headquartered in Chuncheon-si, South Korea.

Ownership
‪‪1.65 M‬‬
Closely held shares
‪‪1.37 M‬‬ (83.46%)
Free Float shares
‪‪272.47 K‬‬ (16.54%)
Closely held shares
‪‪1.37 M‬‬ (83.46%)
Free Float shares
‪‪272.47 K‬‬ (16.54%)
Capital structure
Market cap
‪‪20.51 B‬‬
Debt
‪‪1.21 B‬‬
Cash & equivalents
‪‪9.21 B‬‬
Enterprise value
‪‪12.52 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪20.51 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
‪0.00‬
‪1.30‬
‪2.60‬
‪3.90‬
‪5.20‬
2020
2021
2022
2023
2024
‪0.00‬
‪40.00‬
‪80.00‬
‪120.00‬
‪160.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−18%‬
‪−9%‬
‪0%‬
‪9%‬
‪18%‬
2020
2021
2022
2023
2024
‪‪−9.00 B‬‬
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
‪‪14.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Veterinary Medicines Product
Veterinary Medicines Merchandise
Other
By country
Period: 2024
South Korea
Overseas

Dividends

Dividend yield, history and sustainability

No dividends
233250 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
2020
2021
2022
2023
2024
‪‪−2.20 B‬‬
‪0.00‬
‪‪2.20 B‬‬
‪‪4.40 B‬‬
‪‪6.60 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Assets
Liabilities